Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · ALKEM

ALKEM

HealthcarePharmaceuticals & Biotechnology₹62198 cr market cap
₹5145.00 ▼ -1.48% today As of 19 Nov 2026
52-week low ₹4947.0052-week high ₹5890.00

-11.3% from the 52-week high · +5.6% above the low

Alkem Laboratories Ltd. engages in the development, manufacture, and sale of pharmaceutical products. The company is headquartered in Mumbai, Maharashtra and currently employs 16,871 full-time employees. The company went IPO on 2015-12-23. The firm is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The firm offers its products across various therapeutic areas, such as Anti Infective, Dermatology, Diabetology, Cardiology, Gastroenterology, Osteoporosis, Rheumatology, central nervous system (CNS), Oncology, Urology, Gynecology, and Vitamins, Mineral and Nutrition. Its product range includes Rx Products, Alkem Generics and OTC Product. The Company’s product portfolio includes brands, such as Clavam, Pan, Pan-D, Taxim-O, A To Z NS, Xone, Taxim, Gemcal, Pipzo and Ondem. The firm operates through a segment, Pharmaceuticals. The company has approximately 21 manufacturing facilities at multiple locations in India and the United States. The firm has approximately 800 brands and operates in 40 countries.

The short version. ALKEM reported revenue of ₹4,552 crore for Sep 2026, up 13.8% from a year earlier. Net profit was ₹675 crore (down 11.8% year on year). Return on equity was 16.7% in Mar 2026. Promoter holding was 49.7% in Jun 2026, down 5.96 points over 8 quarters.

1 · The price

How has the stock traded?

ALKEM trades 11.3% below its 52-week high and 5.6% above its 52-week low.

Change over period: —

1M+4.4%
3M-3.0%
6M-3.9%
1Y-8.6%

2 · The business

Is it growing?

Sales, year on year+13.8%

Sep 2026 revenue of ₹4,552 cr.

Profit, year on year-11.8%

Sep 2026 net profit of ₹675 cr.

Net margin14.8%

4.3 pts lower than a year earlier.

3-year growth32.7% profit

Revenue compounded at 9.0% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue45523740360337374001337131443374
Net profit675520236636765664306626
Net margin %14.813.96.617.019.119.79.718.5
EPS (₹)56.4843.4919.7853.1963.9955.5625.5852.34

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue1471212965126681159910634886583447357
Net profit230221651796984164615851127761
Net margin %15.616.714.28.515.517.913.510.3
EPS (₹)192.51181.11150.1982.31137.63132.5794.2663.61

3 · The quality

How well does it turn capital into profit?

Return on equity was 16.7% in Mar 2026; debt to equity is 0.12.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %16.718.117.410.9
Return on capital %18.819.318.414.1
EBITDA margin %22.322.318.814.6
Net margin %15.016.113.88.3

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR9.0%10.9%
Profit CAGR32.7%7.8%
Debt to equity0.12
Interest cover18.9x
Current ratio2.55
P/E ratio30.1

4 · The owners

Who holds it, and are they adding?

Promoter holding49.7%

Down 5.96 pts over 8 quarters.

Foreign institutions10.42%

Up 1.4 pts over 8 quarters.

Domestic institutions22.63%

Up 3.42 pts over 8 quarters.

Mutual fund schemes205

+45 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Change
Promoter55.6655.6655.1353.0451.251.251.249.7-5.96
FII9.0210.159.419.119.489.9710.1610.42+1.4
DII19.2118.0119.4221.821.9321.5421.422.63+3.42
Public16.116.1816.0516.0517.417.317.2517.25+1.15

Mutual fund holdings · Oct 2026

205 schemes hold this stock

160 the month before.

  • HDFC Pharma and Healthcare Fund4.75% of NAV
  • DSP Healthcare Fund4.73% of NAV
  • TATA NIFTY MIDSMALL HEALTHCARE INDEX FUND4.65% of NAV
  • Motilal Oswal Nifty MidSmall Healthcare Index Fund4.64% of NAV
  • ICICI Prudential Healthcare Fund4.61% of NAV
  • UTI - Healthcare Fund3.66% of NAV
  • Mirae Asset Healthcare Fund3.65% of NAV
  • DSP Multi Cap Fund3.32% of NAV

See what mutual funds are buying

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for ALKEM are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about ALKEM

What is the ALKEM share price?

ALKEM (ALKEM) last closed at ₹5,145.00, down 1.48% on the day. Its 52-week range is ₹4,947.00 to ₹5,890.00.

What is the market cap of ALKEM?

ALKEM has a market capitalisation of about ₹62,198 crore. Its price-to-earnings ratio is 30.1.

How are ALKEM's latest results?

ALKEM reported revenue of ₹4,552 crore for Sep 2026, up 13.8% from a year earlier. Net profit was ₹675 crore (down 11.8% year on year). Return on equity was 16.7% in Mar 2026. Promoter holding was 49.7% in Jun 2026, down 5.96 points over 8 quarters.

Who owns ALKEM?

As of Jun 2026, shareholding was: Promoter 49.7%, FII 10.42%, DII 22.63%, Public 17.25%.

How many mutual funds hold ALKEM?

205 mutual fund schemes held ALKEM in October 2026. That compares with 160 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 20 Feb 2026 · Interim Dividend - Rs. 43
  • 08 Aug 2025 · Final Dividend - Rs. 8
  • 14 Feb 2025 · Interim Dividend - Rs. 37
  • 09 Aug 2024 · Final Dividend - Rs. 5
  • 16 Feb 2024 · Interim Dividend - Rs. 35
  • 10 Aug 2023 · Final Dividend - Rs. 10

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.